Multi-target gene therapy AUP1602-C to improve healing and quality of life for diabetic foot ulcer patients: a phase I, open-label, dose-finding study
Background: Diabetic foot ulcer (DFU) is a common and highly morbid complication of diabetes with high unmet medical needs. AUP1602-C, a topical four-in-one gene therapy medicinal product (GTMP), consisting of a Lactococcus cremoris strain that produces fibroblast growth factor-2, interleukin-4, and...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2024-11-01
|
| Series: | Therapeutic Advances in Endocrinology and Metabolism |
| Online Access: | https://doi.org/10.1177/20420188241294134 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841525494165536768 |
|---|---|
| author | Christoph Schindler Jacek Mikosiński Pawel Mikosiński Hanna-Riikka Kärkkäinen Mirka Sanio Jere Kurkipuro Igor Mierau Wesley Smith Aki Vartiainen Laurent Décory Dirk Weber Thomas Wirth Juha Yrjänheikki Sebastian Schellong Haritha Samaranayake |
| author_facet | Christoph Schindler Jacek Mikosiński Pawel Mikosiński Hanna-Riikka Kärkkäinen Mirka Sanio Jere Kurkipuro Igor Mierau Wesley Smith Aki Vartiainen Laurent Décory Dirk Weber Thomas Wirth Juha Yrjänheikki Sebastian Schellong Haritha Samaranayake |
| author_sort | Christoph Schindler |
| collection | DOAJ |
| description | Background: Diabetic foot ulcer (DFU) is a common and highly morbid complication of diabetes with high unmet medical needs. AUP1602-C, a topical four-in-one gene therapy medicinal product (GTMP), consisting of a Lactococcus cremoris strain that produces fibroblast growth factor-2, interleukin-4, and colony-stimulating factor-1, is a promising novel treatment for DFU. Objectives: The aim of this first-in-human study was to investigate whether AUP1602-C is safe and effective in improving wound healing and quality of life (QoL) in patients with non-healing DFU (nhDFU), and to determine the recommended phase II dose. Design: Phase I, single-arm, open-label, uncontrolled, dose escalation study. Methods: The study consisted of four cohorts of patients receiving AUP1602-C as a single dose of 2.5 × 10 5 colony-forming units (CFU)/cm 2 ulcer size or as repeated doses between 2.5 × 10 6 and 2.5 × 10 8 CFU/cm 2 administered 3 times per week for 6 weeks. Within each cohort, a 3 + 3 scheme for monitoring safety, tolerability, and efficacy was applied. Results: In total, 16 patients aged 53–80 years were included, 3 each in the safety and low dose, 4 in the medium dose, and 6 in the high-dose cohort. AUP1602-C demonstrated a favorable safety profile with almost 100% dosing compliance. The most frequently reported side effect related to treatment was skin maceration. No serious adverse reactions, systemic toxicity, deaths, or side effects suggestive of immunogenicity, hypersensitivity, allergic reaction, or dose-limiting toxicities related to treatment were reported. No biodistribution events were observed and shedding-related events were rare and did neither show accumulation nor dose dependency. The recommended phase II dose of 2.5 × 10 8 CFU/cm 2 demonstrated complete healing in 83% of patients without recurrence of ulcers during follow-up. Conclusion: AUP1602-C was safe and well tolerated and demonstrated dose-dependent efficacy in patients with nhDFU. Data supports further clinical development of AUP1602-C. Trial registration: The study was registered in ClinicalTrials.gov (NCT04281992) and ClinicalTrialsRegister.eu (2018-003415-22). |
| format | Article |
| id | doaj-art-d62825e4b1614b6989ec62c8e21d41b2 |
| institution | Kabale University |
| issn | 2042-0196 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Endocrinology and Metabolism |
| spelling | doaj-art-d62825e4b1614b6989ec62c8e21d41b22025-01-17T12:03:34ZengSAGE PublishingTherapeutic Advances in Endocrinology and Metabolism2042-01962024-11-011510.1177/20420188241294134Multi-target gene therapy AUP1602-C to improve healing and quality of life for diabetic foot ulcer patients: a phase I, open-label, dose-finding studyChristoph SchindlerJacek MikosińskiPawel MikosińskiHanna-Riikka KärkkäinenMirka SanioJere KurkipuroIgor MierauWesley SmithAki VartiainenLaurent DécoryDirk WeberThomas WirthJuha YrjänheikkiSebastian SchellongHaritha SamaranayakeBackground: Diabetic foot ulcer (DFU) is a common and highly morbid complication of diabetes with high unmet medical needs. AUP1602-C, a topical four-in-one gene therapy medicinal product (GTMP), consisting of a Lactococcus cremoris strain that produces fibroblast growth factor-2, interleukin-4, and colony-stimulating factor-1, is a promising novel treatment for DFU. Objectives: The aim of this first-in-human study was to investigate whether AUP1602-C is safe and effective in improving wound healing and quality of life (QoL) in patients with non-healing DFU (nhDFU), and to determine the recommended phase II dose. Design: Phase I, single-arm, open-label, uncontrolled, dose escalation study. Methods: The study consisted of four cohorts of patients receiving AUP1602-C as a single dose of 2.5 × 10 5 colony-forming units (CFU)/cm 2 ulcer size or as repeated doses between 2.5 × 10 6 and 2.5 × 10 8 CFU/cm 2 administered 3 times per week for 6 weeks. Within each cohort, a 3 + 3 scheme for monitoring safety, tolerability, and efficacy was applied. Results: In total, 16 patients aged 53–80 years were included, 3 each in the safety and low dose, 4 in the medium dose, and 6 in the high-dose cohort. AUP1602-C demonstrated a favorable safety profile with almost 100% dosing compliance. The most frequently reported side effect related to treatment was skin maceration. No serious adverse reactions, systemic toxicity, deaths, or side effects suggestive of immunogenicity, hypersensitivity, allergic reaction, or dose-limiting toxicities related to treatment were reported. No biodistribution events were observed and shedding-related events were rare and did neither show accumulation nor dose dependency. The recommended phase II dose of 2.5 × 10 8 CFU/cm 2 demonstrated complete healing in 83% of patients without recurrence of ulcers during follow-up. Conclusion: AUP1602-C was safe and well tolerated and demonstrated dose-dependent efficacy in patients with nhDFU. Data supports further clinical development of AUP1602-C. Trial registration: The study was registered in ClinicalTrials.gov (NCT04281992) and ClinicalTrialsRegister.eu (2018-003415-22).https://doi.org/10.1177/20420188241294134 |
| spellingShingle | Christoph Schindler Jacek Mikosiński Pawel Mikosiński Hanna-Riikka Kärkkäinen Mirka Sanio Jere Kurkipuro Igor Mierau Wesley Smith Aki Vartiainen Laurent Décory Dirk Weber Thomas Wirth Juha Yrjänheikki Sebastian Schellong Haritha Samaranayake Multi-target gene therapy AUP1602-C to improve healing and quality of life for diabetic foot ulcer patients: a phase I, open-label, dose-finding study Therapeutic Advances in Endocrinology and Metabolism |
| title | Multi-target gene therapy AUP1602-C to improve healing and quality of life for diabetic foot ulcer patients: a phase I, open-label, dose-finding study |
| title_full | Multi-target gene therapy AUP1602-C to improve healing and quality of life for diabetic foot ulcer patients: a phase I, open-label, dose-finding study |
| title_fullStr | Multi-target gene therapy AUP1602-C to improve healing and quality of life for diabetic foot ulcer patients: a phase I, open-label, dose-finding study |
| title_full_unstemmed | Multi-target gene therapy AUP1602-C to improve healing and quality of life for diabetic foot ulcer patients: a phase I, open-label, dose-finding study |
| title_short | Multi-target gene therapy AUP1602-C to improve healing and quality of life for diabetic foot ulcer patients: a phase I, open-label, dose-finding study |
| title_sort | multi target gene therapy aup1602 c to improve healing and quality of life for diabetic foot ulcer patients a phase i open label dose finding study |
| url | https://doi.org/10.1177/20420188241294134 |
| work_keys_str_mv | AT christophschindler multitargetgenetherapyaup1602ctoimprovehealingandqualityoflifefordiabeticfootulcerpatientsaphaseiopenlabeldosefindingstudy AT jacekmikosinski multitargetgenetherapyaup1602ctoimprovehealingandqualityoflifefordiabeticfootulcerpatientsaphaseiopenlabeldosefindingstudy AT pawelmikosinski multitargetgenetherapyaup1602ctoimprovehealingandqualityoflifefordiabeticfootulcerpatientsaphaseiopenlabeldosefindingstudy AT hannariikkakarkkainen multitargetgenetherapyaup1602ctoimprovehealingandqualityoflifefordiabeticfootulcerpatientsaphaseiopenlabeldosefindingstudy AT mirkasanio multitargetgenetherapyaup1602ctoimprovehealingandqualityoflifefordiabeticfootulcerpatientsaphaseiopenlabeldosefindingstudy AT jerekurkipuro multitargetgenetherapyaup1602ctoimprovehealingandqualityoflifefordiabeticfootulcerpatientsaphaseiopenlabeldosefindingstudy AT igormierau multitargetgenetherapyaup1602ctoimprovehealingandqualityoflifefordiabeticfootulcerpatientsaphaseiopenlabeldosefindingstudy AT wesleysmith multitargetgenetherapyaup1602ctoimprovehealingandqualityoflifefordiabeticfootulcerpatientsaphaseiopenlabeldosefindingstudy AT akivartiainen multitargetgenetherapyaup1602ctoimprovehealingandqualityoflifefordiabeticfootulcerpatientsaphaseiopenlabeldosefindingstudy AT laurentdecory multitargetgenetherapyaup1602ctoimprovehealingandqualityoflifefordiabeticfootulcerpatientsaphaseiopenlabeldosefindingstudy AT dirkweber multitargetgenetherapyaup1602ctoimprovehealingandqualityoflifefordiabeticfootulcerpatientsaphaseiopenlabeldosefindingstudy AT thomaswirth multitargetgenetherapyaup1602ctoimprovehealingandqualityoflifefordiabeticfootulcerpatientsaphaseiopenlabeldosefindingstudy AT juhayrjanheikki multitargetgenetherapyaup1602ctoimprovehealingandqualityoflifefordiabeticfootulcerpatientsaphaseiopenlabeldosefindingstudy AT sebastianschellong multitargetgenetherapyaup1602ctoimprovehealingandqualityoflifefordiabeticfootulcerpatientsaphaseiopenlabeldosefindingstudy AT harithasamaranayake multitargetgenetherapyaup1602ctoimprovehealingandqualityoflifefordiabeticfootulcerpatientsaphaseiopenlabeldosefindingstudy |